2022-11-08T09:46:32-06:00 2021-12-31 231406493 MORISON COGEN LLP 484 NORRISTOWN RD STE 100 BLUE BELL PA 19422 990 2021-01-01 232818395 NATIONAL COMPREHENSIVE CANCER NETWORK NATI 2156900300 3025 CHEMICAL ROAD 100 PLYMOUTH MEETING PA 19462 EILEEN BOSCIA CHIEF FINANCAL OFFICER 2156900300 2022-11-03 1 EILEEN BOSCIA 999009999 JOSEPH M KISTNER CPA P00157086 2674403000 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z ROBERT W CARLSON MD 3025 CHEMICAL ROAD 100 PLYMOUTH MEETING PA 19462 46211501 0 X WWW.NCCN.ORG X 1993 DE NCCN IS DEDICATED TO IMPROVING AND FACILITATING QUALITY, EFFECTIVE, EQUITABLE, AND ACCESSIBLE CANCER CARE SO ALL PATIENTS CAN LIVE BETTER LIVES. 34 34 160 1726 255732 173063 20946289 19295605 21973829 23520158 1043214 1382823 1645498 2012915 45608830 46211501 3446540 1828373 0 0 19912954 21445164 0 0 612116 8598363 6956874 31957857 30230411 13650973 15981090 95474983 114912916 22350961 24342347 73124022 90570569 X NCCN IS DEDICATED TO IMPROVING AND FACILITATING QUALITY, EFFECTIVE, EQUITABLE, AND ACCESSIBLE CANCER CARE SO ALL PATIENTS CAN LIVE BETTER LIVES. 0 0 14186169 21855450 NCCN GUIDELINES, NCCN CONTENT & EDUCATIONAL PROGRAMS:WITH EXPERTS FROM MAJOR ACADEMIC CANCER CENTERS, DEVELOP AND UPDATE CLINICAL PRACTICE GUIDELINES FOR TREATMENT OF CANCER; INCLUDES BOTH DISTRIBUTION OF GUIDELINES FOR NON-COMMERCIAL USE AS WELL AS CERTAIN EDUCATIONAL CONFERENCES AND SYMPOSIA TO COMMUNICATE CONTENT FREE OF CHARGE. 3740129 2913469 PATIENT INFORMATION:DISSEMINATION OF PATIENT INFORMATION BASED ON GUIDELINES; DEVELOPMENT AND DISSEMINATION OF MEASURES TO ASSESS THE QUALITY OF CARE. 3476251 1828373 ONCOLOGY RESEARCH:DEVELOPMENT OF A CLINICAL RESEARCH NETWORK OF PHYSICIANS AT MEMBER ACADEMIC CANCER CENTERS TO FACILITATE THE CONDUCT OF STUDIES TO ADVANCE STATE-OF-THE-ART CANCER CARE. 2532021 764154 DEVELOPMENT OF OTHER PUBLIC AND PROFESSIONAL INFORMATION PROGRAMS TO FACILITATE ACCESS TO CANCER SPECIALTY SERVICES. 2532021 764154 23934570 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 294 0 1 160 1 1 1 0 0 0 0 0 0 0 0 0 X 34 34 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MS MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X EILEEN BOSCIA 2156900300 3025 CHEMICAL ROAD SUITE 100 PLYMOUTH MEETING PA 19462 RONALD S WALTERS MD MBA MHA MS DIRECTOR, CHAIR 2.00 X 0 0 0 JOHN W SWEETENHAM MD FACP FRCP DIRECOTR, VICE-CHAIR 2.00 X 0 0 0 LORI C PICKENS MHA DIRECTOR, SECRETARY, FORMER 2.00 X 0 0 0 REBECCA L CAIRES MBA DIRECTOR, SECRETARY 2.00 X 0 0 0 PATRICK J O'BRIEN MBA DIRECTOR, TREASURER 2.00 X 0 0 0 ROBERT H VONDERHEIDE MD DPHIL DIRECTOR 2.00 X 0 0 0 THEODOROS TEKNOS MD DIRECTOR 2.00 X 0 0 0 RAVI SALGIA MD PHD DIRECTOR 2.00 X 0 0 0 CRAIG A BUNNELL MD MBA MPH DIRECTOR 2.00 X 0 0 0 THOMAS A D'AMICO MD DIRECTOR 2.00 X 0 0 0 KENNETH H COWAN MD PHD DIRECTOR 2.00 X 0 0 0 NANCY E DAVIDSON MD DIRECTOR 2.00 X 0 0 0 ROBERT R MCWILLIAMS MD MSC DIRECTOR 2.00 X 0 0 0 DAVID G PFISTER MD DIRECTOR 2.00 X 0 0 0 LOUIS B HARRISON MD DIRECTOR 2.00 X 0 0 0 LISLE M NABELL MD DIRECTOR 2.00 X 0 0 0 AL B BENSON III MD FACP FASCO DIRECTOR 2.00 X 0 0 0 STEPHEN B EDGE MD FACS FASCO DIRECTOR 2.00 X 0 0 0 TIMOTHY J EBERLEIN MD DIRECTOR 2.00 X 0 0 0 ALBERTO S PAPPO MD DIRECTOR 2.00 X 0 0 0 WILLIAM E CARSON III MD DIRECTOR 2.00 X 0 0 0 DAVID S ETTINGER MD FACP FCCP DIRECTOR 2.00 X 0 0 0 JOSEPH A CALIFANO III MD DIRECTOR 2.00 X 0 0 0 MICHAEL L STEINBERG MD DIRECTOR 2.00 X 0 0 0 ALAN P VENOOK MD DIRECTOR 2.00 X 0 0 0 SAMUEL M SILVER MD PHD MACP DIRECTOR 2.00 X 0 0 0 LAURA W GOFF MD MSCI DIRECTOR 2.00 X 0 0 0 ELIZABETH R PLIMACK MD MS DIRECTOR 2.00 X 0 0 0 SACHIN M APTE MD MBA MS DIRECTOR 2.00 X 0 0 0 RONDEEP BRAR MD DIRECTOR 2.00 X 0 0 0 RICHARD BOLD MD MBA DIRECTOR 2.00 X 0 0 0 RICHARD D SCHULICK MD MBA FACS DIRECTOR 2.00 X 0 0 0 LEE G WILKE MD FACS DIRECTOR 2.00 X 0 0 0 STEVEN J FRANK MD DIRECTOR 2.00 X 0 0 0 ROBERT W CARLSON MD CHIEF EXECUTIVE OFFICER 40.00 2.00 X 986117 0 70084 GARY WEYHMULLER CHIEF OPERATING OFFICER 40.00 2.00 X 549012 0 70084 WUI-JIN KOH MD CHIEF MEDICAL OFFICER 40.00 X 546890 0 44708 CRYSTAL DENLINGER CHIEF SCIENTIFIC OFFICER 40.00 X 222392 0 7854 EILEEN BOSCIA CHIEF FINANCIAL OFFICER 40.00 4.00 X 269175 0 39845 BETH GAFFNEY VP - US & GLOBAL BUSINESS DEVELOPMENT 40.00 1.00 X 222359 0 43600 KRISTINA M GREGORY VP, CLINICAL INFORMATION P 40.00 X 303562 0 42530 LINDA LEACH VP, ADMIN. & HUMAN RESOURC 40.00 X 270013 0 39581 JENNIFER TREDWELL VP, MARKETING & COMMUNICAT 40.00 1.00 X 208664 0 69236 JOSEPH JUNOD SENIOR DIRECTOR, IT 40.00 X 173436 0 51878 3751620 0 479400 49 0 1 0 CLINICAL CARE OPTIONS LLC 12001 SUNRISE VALLEY DRIVE SUITE 3 RESTON VA 20191 MEDICAL EDUCATION PROGRAM SERVICES 1147352 ASTRAZENECA PHARMA LP 1800 CONCORD PIKE WILMINGTON DE 19803 RESEARCH 770000 PFIZER INC 685 THIRD AVE 685/14/MS-08 NEW YORK NY 10017 RESEARCH 713571 BAYER HEALTHCARE PHARMA 100 BAYER BLVD PO BOX 915 WHIPPANY NJ 07981 RESEARCH 317476 ITC TRANSLATIONS USA INC 900 EAST INDIANTOWN ROAD SUITE 302 JUPITER FL 33477 PROFESSIONAL SERVICES 296290 5 4340000 14955605 19295605 LICENSE FEES 900099 8987773 8987773 PERMISSION FEES 900099 6558052 6558052 CONSULTING FEES 900099 2232217 2232217 SUBSCRIPTIONS 900099 1967786 1967786 GUIDELINE DISTRIBUTION 900099 1958589 1958589 1815741 1815741 23520158 1382823 1382823 1757183 1757183 ADVERTISING 541800 255732 255732 255732 46211501 25277341 255732 1382823 1828373 1828373 2573584 1950746 572554 50284 13902946 12496395 987226 419325 834626 733721 77130 23775 3103675 2728443 286820 88412 1030333 905766 95217 29350 271907 150490 121417 74750 16000 58750 930407 886635 43772 117748 66528 51220 249677 94118 155559 805322 332107 473200 15 1939019 1939019 -29543 -37834 8291 806069 806069 445692 445692 182781 182781 HONORARIA 512451 512451 PRINTING AND PUBLICATIO 204577 201421 3156 FEES 123367 112355 11012 DUES & SUBSCRIPTIONS 98501 81274 16862 365 224149 69512 154047 590 30230411 23934570 5683725 612116 18394044 28525911 22336959 12338596 3979326 5698774 1514660 1570910 308912 338510 1289121 1242211 3724752 1941318 1995121 1783434 45656840 63414570 95474983 114912916 4532494 3614196 17818467 20728151 22350961 24342347 X 68469894 86892520 4654128 3678049 73124022 90570569 95474983 114912916 15981090 1465457 0 X X 0 1 X 1 0 X 17844586 16587411 17231822 20946288 19295605 91905712 17844586 16587411 17231822 20946288 19295605 91905712 5129375 86776337 835319 1482180 2187970 2455722 3140006 10101197 86428 139061 173053 145876 174783 719201 15819880 17540902 19536519 21973829 23520158 98391288 201117398 0.43150 0.46100 X SCHEDULE A - PART II SECTION B LINE 10 OTHER INCOME INCLUDES THE FOLLOWING ITEMS: LICENSE FEE REVENUE FOR LICENSING OF NCCN PRODUCTS $8,987,773 PERMISSION FEES 6,558,052 CONSULTING REVENUE 2,232,217 GUIDELINE DISTRIBUTION 1,958,589 SUBSCRIPTION REVENUE FROM THE NCCN COMPENDIA, CHEMOTHERAPY ORDER TEMPLATES AND FLASH UDPATES 1,967,786 TUITION FEES FOR NCCN ACADEMY 499,995 TRENDS SURVEY FEES FOR NCCN TRENDS REPORTS 425,522 EXHIBIT FEES FOR EXHIBITING AT NCCN EDUCATIONAL PROGRAMS 357,900 REGISTRATION FEES FOR NCCN EDUCATIONAL PROGRAMS 268,166 FELLOWSHIP GRANTS 264,158 TOTAL $23,520,158 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 12999 12999 30217412 30230411 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 9851 11281 8037 12999 42168 250000 250000 250000 250000 1000000 1500000 SCHEDULE C PART II-A, LINE 1 LOBBYING EXPENDITURES ON PART II-A, LINE 1 OF $12,999 INCLUDE STAFF TIME ASSOCIATED WITH LOBBYING ACTIVITIES INCLUDING THE REDUCING HEREDITARY CANCER ACT OF 2021, THE SENIOR'S TIMELY ACCESS TO CARE ACT OF 2021, ISSUES OF SURVIVORSHIP CARE AND RISK REDUCING INTERVENTIONS, AS WELL AS, MEETINGS WITH VARIOUS MEMBERS OF CONGRESS AND FEDERAL AGENCIES. 1160795 308066 852729 2563957 1633252 930705 1783434 47676958 1465457 1465457 46211501 0 46211501 30230411 0 30230411 0 30230411 1 ADVENTHEALTH ORLANDO 601 E ROLLINS ST SUITE 400 ORLANDO FL 32803 590724459 501(C)(3) 36892 0 RESEARCH DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BP320 BOSTON MA 02215 043320640 501(C)(3) 184927 0 RESEARCH FOX CHASE CANCER CENTER 333 COTTMAN AVENUE PHILADELPHIA PA 19111 232003072 501(C)(3) 82760 0 RESEARCH H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)(3) 47537 0 RESEARCH HEALTH RESEARCH INC ROSEWELL PARK CANCER CENTER - ELM AND CARLTON STREETS BUFFALO NY 14263 141402155 501(C)(3) 70820 0 RESEARCH HUNTSMAN CANCER INSTITUTE 2000 CIRCLE OF HOPE SALT LAKE CITY UT 84112 876000525 501(C)(3) 38923 0 RESEARCH JOHNS HOPKINS UNIVERSITY 733 N BROADWAY SUITE 117 BALTIMORE MD 21205 520595110 501(C)(3) 42979 0 RESEARCH KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66160 481108830 501(C)(3) 34392 0 RESEARCH MASS GENERAL HOSPITAL 101 HUNTINGTON AVENUE SUITE 210 BOSTON MA 02199 042697983 501(C)(3) 255313 0 RESEARCH MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 73234 0 RESEARCH NORTHWESTERN UNIVERSITY HEALTH SYSTEM 750 N LAKE SHORE DRIVE 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 64604 0 RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA 1855 FOLSOM STREET ROOM 425 SAN FRANCISCO CA 94143 946036493 501(C)(3) 24089 0 RESEARCH STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501(C)(3) 105625 0 RESEARCH THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER 1960 KENNY ROAD COLUMBUS OH 43221 316401599 501(C)(3) 142713 0 RESEARCH THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE AVE UNIT 176 HOUSTON TX 77030 746001118 501(C)(3) 162608 0 RESEARCH UNIV OF ALABAMA AT BIRMINGHAM 1720 UNIVERSITY BLVD BIRMINGHAM AL 35294 636005396 501(C)(3) 52720 0 RESEARCH UNIVERSITY OF WASHINGTON 825 EASTLAKE AVENUE SEATLE WA 98109 916001537 115 50772 0 RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER DEPARTMENT OF FINANCE AT40303 ATLANTA GA 311920303 620476822 501(C)(3) 79335 0 RESEARCH UNIVERSITY OF SOUTHERN CA STE 205 UNIVERSITY GARDENS BLDG LOS ANGELES CA 90089 951642394 501(C)(3) 53432 0 RESEARCH UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)(3) 89966 0 RESEARCH WASHINGTON UNIVERSITY 700 ROSEDALE AVENUE ST LOUIS MO 63112 430653611 501(C)(3) 58956 0 RESEARCH YALE UNIVERSITY 100 CHURCH STREET SOUTH SUITE A160 NEW HAVEN CT 06520 060646973 501(C)(3) 60522 0 RESEARCH 25 2 PART I, LINE 2: NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) ENTERS INTO RESEARCH GRANT AGREEMENTS WITH INSTITUTIONS TO CONDUCT RESEARCH FOR INDIVIDUAL STUDY PROJECTS APPROVED BY NCCN'S SCIENTIFIC REVIEW COMMITTEES. THE SCOPE AND NATURE OF STUDIES TO BE PERFORMED BY GRANT RECIPIENTS ARE IN ACCORDANCE WITH THE APPROVED PROTOCOLS DEVELOPED BY THE PRINCIPAL INVESTIGATORS AND CONSISTENT WITH THE PROPOSALS SUBMITTED TO AND APPROVED BY THE NCCN SCIENTIFIC REVIEW COMMITTEES. PRINCIPAL INVESTIGATORS OR THEIR INSTITUTIONS MUST ATTEST THAT THEY WILL ABIDE BY THE TERMS OF NCCN RESEARCH AGREEMENTS AND THAT THE PRINCIPAL INVESTIGATORS HAVE NOT BEEN DEBARRED OR DISQUALIFIED UNDER ANY RELEVANT STATUTES. IF AN INSTITUTION DOES NOT COMMENCE A STUDY WITHIN THE REQUIRED TIMELINE, NCCN MAY REQUEST THE INVESTIGATOR SUBMIT A CORRECTIVE ACTION PLAN FOR NCCN'S APPROVAL OR TERMINATE THE STUDY. DURING THE TERM OF THE GRANT, INSTITUTIONS REPORT TO NCCN ON A MONTHLY OR QUARTERLY BASIS. REPORTS INCLUDE AN UPDATE ON THE STATUS AND PROGRESS OF THE FUNDED STUDIES INCLUDING AN ASSESSMENT OF TOTAL ENROLLMENT OR STUDY PROGRESS, ELIGIBILITY, AND ACCRUAL OF PATIENTS AS APPLICABLE. IN CONSIDERATION FOR PERFORMANCE OF THE STUDY, NCCN DISTRIBUTES GRANT MONIES TO INSTITUTIONS WHEN CERTAIN BENCHMARK MILESTONES ARE MET AND FINAL PAYMENT IS DISBURSED UPON RECEIPT OF THE FINAL BENCHMARK MILESTONE IN THE FORM OF FINAL REPORTS AND / OR MANUSCRIPTS. INSTITUTIONS THAT DO NOT ENROLL OR COMPLETE THEIR STUDIES FULLY ARE REQUIRED TO RECONCILE STUDY EXPENSES AT TERMINATION OR COMPLETION AND RETURN UNUSED FUNDS TO NCCN WHICH ARE IN TURN RETURNED TO THE GRANTOR. X X X 0 0 0 0 0 0 0 0 0 ROBERT W CARLSON MD CHIEF EXECUTIVE OFFICER 823360 0 162757 0 0 0 29000 0 41084 0 1056201 0 0 0 GARY WEYHMULLER CHIEF OPERATING OFFICER 491602 0 57410 0 0 0 29000 0 41084 0 619096 0 0 0 WUI-JIN KOH MD CHIEF MEDICAL OFFICER 489044 0 57846 0 0 0 29000 0 15708 0 591598 0 0 0 KRISTINA M GREGORY VP, CLINICAL INFORMATION P 271270 0 32292 0 0 0 27436 0 15094 0 346092 0 0 0 LINDA LEACH VP, ADMIN. & HUMAN RESOURC 241260 0 28753 0 0 0 24487 0 15094 0 309594 0 0 0 EILEEN BOSCIA CHIEF FINANCIAL OFFICER 240609 0 28566 0 0 0 24328 0 15517 0 309020 0 0 0 JENNIFER TREDWELL VP, MARKETING & COMMUNICAT 185687 0 22977 0 0 0 19568 0 49668 0 277900 0 0 0 BETH GAFFNEY VP - US & GLOBAL BUSINESS DEVELOPMEN 217859 0 4500 0 0 0 2932 0 40668 0 265959 0 0 0 CRYSTAL DENLINGER CHIEF SCIENTIFIC OFFICER 222392 0 0 0 0 0 0 0 7854 0 230246 0 0 0 JOSEPH JUNOD SENIOR DIRECTOR, IT 163236 0 10200 0 0 0 11293 0 40585 0 225314 0 0 0 FORM 990, PART I, LINE 6, VOLUNTEERS: NCCN HAD 1,726 VOLUNTEERS COMMIT APPROXIMATELY 40,303 VOLUNTEER HOURS AS PANEL MEMBERS UPDATING EACH OF THE NCCN GUIDELINES FOR CANCER TREATMENT. FORM 990, PART VI, SECTION B, LINE 11B NCCN PROVIDES A DRAFT COPY OF THE FORM 990 TO THE FINANCE COMMITTEE OF THE BOARD OF DIRECTORS FOR ITS REVIEW AND APPROVAL PRIOR TO FILING THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C NCCN REQUIRES OFFICERS, DIRECTORS, AND KEY EMPLOYEES TO ANNUALLY COMPLETE A CONFLICT OF INTEREST QUESTIONNAIRE. THIS QUESTIONNAIRE SHALL BE UPDATED AS NECESSARY TO REFLECT CHANGES DURING THE COURSE OF THE YEAR. COMPLETED QUESTIONNAIRES SHALL BE AVAILABLE FOR INSPECTION BY ANY BOARD MEMBER AND MAY BE REVIEWED BY NCCN'S LEGAL COUNSEL. SENIOR NCCN STAFF REVIEW THE CONFLICT OF INTEREST FORMS ANNUALLY, PROVIDE A REPORT TO THE EXECUTIVE COMMITTEE AND TAKE CORRECTIVE ACTION IF NEEDED. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF NCCN'S CHIEF EXECUTIVE OFFICER (CEO) IS REVIEWED PERIODICALLY BY AN INDEPENDENT ORGANIZATION ENGAGED BY THE CHAIRMAN OF NCCN'S BOARD OF DIRECTORS TO CONDUCT A SALARY COMPARABILITY STUDY AND SURVEY. THE INFORMATION FROM THE SURVEY CONDUCTED BY THE INDEPENDENT ORGANIZATION IS FORWARDED TO NCCN'S EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS FOR THEIR REVIEW. EACH YEAR, THE EXECUTIVE COMMITTEE OF NCCN'S BOARD OF DIRECTORS RECEIVES INFORMATION REGARDING THE CEO'S PAST SALARY HISTORY AS WELL AS THE CEO'S ACCOMPLISHMENTS. NCCN'S EXECUTIVE COMMITTEE SCHEDULES A CONFERENCE CALL TO REVIEW THIS INFORMATION AND TO DISCUSS RECOMMENDATIONS FOR THE CEO'S SALARY AND BONUS FOR THE UPCOMING YEAR. FORM 990, PART VI, SECTION B, LINE 15B THE COMPENSATION OF NCCN'S CHIEF OPERATING OFFICER (COO), CHIEF MEDICAL OFFICER, CHIEF SCIENTIFIC OFFICER, AND CHIEF FINANCIAL OFFICER (CFO) IS REVIEWED PERIODICALLY BY AN INDEPENDENT ORGANIZATION ENGAGED BY THE CEO OF NCCN. THE ORGANIZATION CONDUCTS A SALARY COMPARABILITY STUDY AND SURVEY FOR COMPARABLE POSITIONS IN SIMILAR ORGANIZATIONS. THE CEO REVIEWS THE SALARY STUDY AND SURVEY TO DETERMINE THE COMPENSATION FOR THE ABOVE KEY EMPLOYEES OF NCCN. FORM 990, PART VI, SECTION C, LINE 19 NCCN MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XII, LINE 2C: THE FINANCE COMMITTEE ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT AND SELECTION OF AN INDEPENDENT ACCOUNTANT. NCCN FOUNDATION 3025 CHEMICAL ROAD SUITE 100 PLYMOUTH MEETING PA 19462 271536314 FOUNDATION DE 501(C)(3) LINE 7 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 NCCN FOUNDATION L 2075280 FMV NCCN FOUNDATION O 910707 FMV NCCN FOUNDATION P 46388 FMW PART V LINE 2, COLUMN C PROFESSIONAL FEES $28,000 TRAVEL AND MEETINGS 88 OFFICE EXPENSE 11,551 SUPPLIES AND PRINTING 1,540 OTHER EXPENSES 937 RESEARCH PROGRAM 3,646 MARKETING AND PUBLIC RELATIONS 427 TELEPHONE 199 TOTAL PART V - LINE 2(3) $46,388